He will report to Steve Davis, Acadia's president and chief executive officer and serve as a member of the company's executive management committee.
The company previously announced in February that Glenn F. Baity, who served as executive vice president, general counsel and secretary since 2004, would be retiring. Baity will remain with Acadia through completion of a transition period.
From 2006 until 2017, Kim held several senior legal positions at Teva Pharmaceuticals. Before joining Teva, he was deputy general counsel at IVAX Corp.
Earlier in his career, Kim was a senior lawyer at Transamerica Corp., practiced law at Pillsbury, Madison and Sutro and clerked for Judge Vaughn Walker of the US District Court, Northern District of California.
Kim received his J.D. degree from Columbia University School of Law and his A.B. in English Literature and Economics from Stanford University.
Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials